Intercept Pharmaceuticals, Inc. (ICPT) Shares Sold by Alliancebernstein L.P.

Alliancebernstein L.P. reduced its position in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) by 0.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,909 shares of the biopharmaceutical company’s stock after selling 30 shares during the period. Alliancebernstein L.P.’s holdings in Intercept Pharmaceuticals were worth $1,008,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in ICPT. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Intercept Pharmaceuticals by 14.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 132 shares during the period. Pacer Advisors Inc. raised its position in Intercept Pharmaceuticals by 21.6% in the first quarter. Pacer Advisors Inc. now owns 1,861 shares of the biopharmaceutical company’s stock worth $210,000 after buying an additional 330 shares during the period. Swiss National Bank raised its position in Intercept Pharmaceuticals by 2.2% in the first quarter. Swiss National Bank now owns 28,500 shares of the biopharmaceutical company’s stock worth $3,223,000 after buying an additional 600 shares during the period. Creative Planning raised its position in Intercept Pharmaceuticals by 17.1% in the first quarter. Creative Planning now owns 4,627 shares of the biopharmaceutical company’s stock worth $523,000 after buying an additional 675 shares during the period. Finally, BNP Paribas Arbitrage SA raised its position in Intercept Pharmaceuticals by 24.7% in the first quarter. BNP Paribas Arbitrage SA now owns 5,006 shares of the biopharmaceutical company’s stock worth $566,000 after buying an additional 990 shares during the period. 83.05% of the stock is owned by hedge funds and other institutional investors.

Shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) opened at 104.08 on Friday. The stock’s market capitalization is $2.61 billion. The firm’s 50-day moving average price is $117.73 and its 200-day moving average price is $117.69. Intercept Pharmaceuticals, Inc. has a 12 month low of $96.63 and a 12 month high of $172.95.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its earnings results on Monday, July 31st. The biopharmaceutical company reported ($3.46) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($3.62) by $0.16. The business had revenue of $30.89 million for the quarter, compared to analysts’ expectations of $27.50 million. Intercept Pharmaceuticals had a negative return on equity of 135.24% and a negative net margin of 543.35%. The business’s revenue for the quarter was up 459.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($3.14) EPS. On average, equities research analysts forecast that Intercept Pharmaceuticals, Inc. will post ($14.05) EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Intercept Pharmaceuticals, Inc. (ICPT) Shares Sold by Alliancebernstein L.P.” was first reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/08/19/intercept-pharmaceuticals-inc-icpt-shares-sold-by-alliancebernstein-l-p-updated-updated.html.

A number of research firms have recently weighed in on ICPT. Credit Suisse Group set a $201.00 price objective on Intercept Pharmaceuticals and gave the stock a “buy” rating in a research note on Saturday, June 3rd. Oppenheimer Holdings, Inc. set a $200.00 price target on Intercept Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, May 4th. Cantor Fitzgerald set a $60.00 price target on Intercept Pharmaceuticals and gave the company a “sell” rating in a research note on Thursday, May 4th. Laidlaw reissued a “hold” rating and set a $119.00 price target (up from $115.00) on shares of Intercept Pharmaceuticals in a research note on Tuesday, August 1st. Finally, Zacks Investment Research raised Intercept Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, May 8th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $203.67.

In related news, Director Daniel G. Welch sold 217 shares of the company’s stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $126.76, for a total value of $27,506.92. Following the transaction, the director now directly owns 3,710 shares in the company, valued at $470,279.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Lisa Bright sold 698 shares of the company’s stock in a transaction that occurred on Thursday, June 1st. The shares were sold at an average price of $110.73, for a total value of $77,289.54. Following the completion of the transaction, the insider now owns 24,711 shares in the company, valued at $2,736,249.03. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 47,462 shares of company stock worth $6,130,938. Insiders own 9.20% of the company’s stock.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Institutional Ownership by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

What are top analysts saying about Intercept Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Intercept Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit